With production and cost figures pre-reported, FY21 results held few surprises and were broadly in-line with Morgans estimates. A soft start to FY22 is expected, with planned mill shutdowns in the current quarter along with preventative maintenance across several open pits.
Profit was higher than the broker's estimate, driven by the timing of stamp duty payment related to the Tropicana purchase. Morgans retains its Add rating and $3.93 target price.
Target price is $3.93 Current Price is $2.39 Difference: $1.54
If RRL meets the Morgans target it will return approximately 64% (excluding dividends, fees and charges).Current consensus price target is $3.38, suggesting upside of 41.5% (ex-dividends)
The company's fiscal year ends in June.
- Forums
- ASX - By Stock
- RRL
- Under valued
RRL
regis resources limited
Add to My Watchlist
2.23%
!
$4.39

Under valued, page-130
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.39 |
Change
-0.100(2.23%) |
Mkt cap ! $3.316B |
Open | High | Low | Value | Volume |
$4.47 | $4.53 | $4.37 | $16.81M | 3.793M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 51252 | $4.36 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.39 | 7201 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4000 | 4.350 |
4 | 7325 | 4.300 |
1 | 1174 | 4.270 |
2 | 1435 | 4.250 |
1 | 2700 | 4.240 |
Price($) | Vol. | No. |
---|---|---|
4.420 | 5266 | 1 |
4.550 | 1000 | 1 |
4.570 | 222 | 1 |
4.580 | 6000 | 1 |
4.610 | 180 | 1 |
Last trade - 16.17pm 27/06/2025 (20 minute delay) ? |
Featured News
RRL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online